On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.

NetworkNewsBreaks – CymaBay Therapeutics, Inc. (NASDAQ: CBAY) Closes $144M Public Offering

Company: CymaBay Therapeutics, Inc. (CBAY)
Category: News

CymaBay Therapeutics, Inc. (NASDAQ: CBAY) recently announced the closing of a public offering of 13.34 million shares, including the sale of additional 1,740,000 shares of common stock pursuant to the full exercise of the over-allotment option granted to the underwriters. The common stock public offering was part of a bid to fund the ongoing development of its drug Seladelpar, a treatment for autoimmune liver disease, primary biliary cholangitis (“PBC”) and nonalcoholic steatohepatitis (“NASH”). The company sold the shares at an offering price of $10.80 per share resulting in the gross proceeds of approximately $144 million prior to underwriting discounts and commissions.

To view the full press release, visit http://nnw.fm/074Bu

About CymaBay

CymaBay Therapeutics, Inc. (CBAY) is a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet medical need. Seladelpar is a potent, selective, orally active PPARδ agonist currently in development for the treatment of patients with the autoimmune liver disease, primary biliary cholangitis (“PBC”) and nonalcoholic steatohepatitis (“NASH”). Two Phase 2 studies of seladelpar established proof of concept in PBC. CymaBay is currently planning to advance development of seladelpar into Phase 3 for PBC and Phase 2 for NASH. For more information, visit the company’s website at www.CymaBay.com.

More from NetworkNewsBreaks

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

For more information, please visit https://www.networknewswire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Doge Coin

Dogecoin

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 212.418.1217